4-<(methylsulfonyl)amino>benzoyl chloride | 63421-72-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-<(methylsulfonyl)amino>benzoyl chloride
• 英文别名: 4-[(methyl-sulfonyl)amino]benzoyl chloride；4-[(Methylsulfonyl)amino]benzoyl chloride；4-(methanesulfonamido)benzoyl chloride
• CAS: 63421-72-7
• 化学式: C₈H₈ClNO₃S
• 分子量: 233.675
• InChiKey: XIWZUWWVOULHGZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  71.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-<(methylsulfonyl)amino>benzoyl chloride 在 palladium on activated charcoal 氢气 作用下， 以 四氢呋喃 、 水 为溶剂， 25.0 ℃ 、344.73 kPa 条件下， 反应 25.0h， 生成 1-<4-<(methylsulfonyl)amino>benzoyl>piperazine hydrochloride
  参考文献：
  名称：

  Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity

  摘要：

  Several (aryloxy)propanolamines and related compounds (i.e. 5-13, 16-18, 20-24, 27-33, 35, 37-39, 41, and 42) were synthesized and investigated for their class III electrophysiological activity and class II (beta-blocking) effects with use of in vitro and in vivo models. Structure-activity relationships are discussed for a series of 30 compounds. A number of these compounds prolonged the action potential duration at 95% repolarization of isolated canine cardiac Purkinje fibers by 20% (C20APD95) at concentrations of less than 1.0 microM, with no significant effects on cardiac conduction. beta-Adrenergic receptor binding studies showed that some of these compounds were 2-20 times more potent for cardiac beta 1 receptors than for beta 2 receptors. In particular, compounds 32, 41, 1, and especially (S)-1 were found to be orally active class III agents in anesthetized mongrel dogs (1 or 3 mg/kg, id) and efficacious at suppressing programmed electrical stimulation induced arrhythmias in halothane-anesthetized dogs. The profile of these compounds was similar to that found for sotalol. Compound (S)-1, which was more potent than sotalol in the PES study and equieffective in the halothane/epinephrine dog model, is being investigated further as a combined class III/II antiarrhythmic agent.

  DOI：

  10.1021/jm00172a033
• 作为产物：
  描述：

  4-甲磺酰氨基苯甲酸 在 氯化亚砜 作用下， 反应 2.0h， 生成 4-<(methylsulfonyl)amino>benzoyl chloride
  参考文献：
  名称：

  Cytotoxic potential of novel 6,7-dimethoxyquinazolines

  摘要：

  Herein, we report the synthesis and cytotoxicity of a series of substituted 6,7-dimethoxyquinazoline derivatives. The cytotoxic activity of all synthesized compounds has been evaluated against HCT116p53(+/+) and HCT116p53(-/-) colon cancer cells and a HEY ovarian cancer cell line naturally resistant to cisplatin. Nine of the tested compounds showed significant cytotoxicity in all cell lines at 10 mu M. The most promising derivative (7c) showed IC(50)values of 0.7 and 1.7 mu M in the two colon cancer cell lines. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.12.020

文献信息

• Substituted sulfonamidobenzamides, antiarrhythmic agents and
  申请人：Schering A.G.

  公开号：US04544654A1

  公开（公告）日：1985-10-01

  Novel substituted sulfonamidobenzamides are described as useful antiarrhythmic agents. Their use in the treatment of cardiac arrhythmias, especially re-entrant arrhythmias, via the prolongation of the action potential of cardiac tissue is provided. Pharmaceutical formulations containing such compounds are also disclosed.

  小说替代磺胺基苯甲酰胺被描述为有用的抗心律失常药物。通过延长心脏组织的动作电位来治疗心律失常，特别是再入性心律失常。还公开了含有这些化合物的药物配方。
• Derivatized alkanolamines as cardiovascular agents
  申请人：Schering AG

  公开号：US05051423A1

  公开（公告）日：1991-09-24

  Novel derivatized alkanolamines of the following structural formula ##STR1## are described as useful cardiovascular agents. Most especially described is their usefulness as cardiovascular agents exhibiting an antiarrhythmic effect. Said antiarrhythmic effect is of a combination Class II/Class III variety. Pharmaceutical formulations containing such compounds are also described.

  以下结构式##STR1##的新型衍生烷醇胺被描述为有用的心血管药物。特别描述了它们作为表现出抗心律失常作用的心血管药物的有用性。所述的抗心律失常作用属于II类/III类结合型。还描述了含有这类化合物的药物配方。
• Substituted sulfonamidobenzamides and method of treating arrhythmias
  申请人：Schering A.G.

  公开号：US04629739A1

  公开（公告）日：1986-12-16

  Novel substituted sulfonamidobenzamides are described as useful antiarrhythmic agents. Their use in the treatment of cardiac arrhythmias, especially re-entrant arrhythmias, via the prolongation of the action potential of cardiac tissue is provided. Pharmaceutical formulations containing such compounds are also disclosed.

  小说替代磺胺基苯甲酰胺被描述为有用的抗心律失常药物。它们通过延长心脏组织的动作电位来治疗心律失常，特别是再进入性心律失常。还公开了含有这些化合物的药物制剂。
• Synthesis and class III type antiarrhythmic activity of 4-aroyl (and aryl)-1-aralkylpiperazines
  作者：Ramesh M. Kanojia、Joseph J. Salata、Jack Kauffman

  DOI：10.1016/s0960-894x(00)00581-3

  日期：2000.12

  The synthesis and in vitro Class III antiarrhythmic activity of several 4-aroyl (and aryl)-1-aralkylpiperazine and piperidine derivatives are described. Among several potent compounds identified in the series, RWJ-28810 (3), with its EC20 of 3 nM, ranks as one of the most potent (in vitro) compounds reported.

  描述了几种4-芳酰基（和芳基）-1-芳烷基哌嗪和哌啶衍生物的合成和体外Ⅲ类抗心律失常活性。在该系列中鉴定出的几种有效化合物中，RWJ-28810（3）的EC20为3 nM，被列为最有效的（体外）化合物之一。
• Synthesis, cardiac electrophysiology, and .beta.-blocking activity of novel arylpiperazines with potential as class II/III antiarrhythmic agents
  作者：Gary B. Phillips、Thomas K. Morgan、William C. Lumma、Robert P. Gomez、Joan M. Lind、Randall Lis、Thomas Argentieri、Mark E. Sullivan

  DOI：10.1021/jm00082a016

  日期：1992.2

  competitive binding assay and three had beta 1-receptor selectivity. Compared to sotalol, a reference class II/III agent, arylpiperazine 7a (4-[(methylsulfonyl)amino]-N-[(4- phenylpiperazin-2-yl)methyl]benzamide) demonstrated beta 1-selectivity and was 1 order of magnitude more potent in the in vitro class III and the beta 1-receptor screens. Compound 7a was evaluated further and found to be effective in

  尝试制备一系列新颖的芳基哌嗪，以将II类（β受体阻滞）和III类抗心律失常特性合并到一个分子中。制备新化合物的关键步骤涉及区域选择性杂环的形成。除四种化合物外，所有化合物均显着延长了犬心脏浦肯野纤维的动作电位持续时间（III类活性）。除一种化合物外，所有化合物均在竞争性结合试验中显示出β受体亲和力，而三种具有β1受体选择性。与索他洛尔相比，参考II / III类药物芳基哌嗪7a（4-[（（甲基磺酰基）氨基] -N-[（4-苯基哌嗪-2-基）甲基]苯甲酰胺）表现出β1选择性，约为1级。在体外III类和β1受体筛选中，更强的效价。